We demonstrated that administration of selegiline, a registered, irreversible MAO-B inhibitor anti-Parkinson medication with propargylamine moiety in its chemical structure, has attenuated the kanamycin-induced hearing loss (an AGIHL) in mice. This evidence concerns the gene MAOB and Parkinson disease.